AU2001261752A1 - Compositions and methods for treating otic, ophthalmic and nasal infections - Google Patents
Compositions and methods for treating otic, ophthalmic and nasal infectionsInfo
- Publication number
- AU2001261752A1 AU2001261752A1 AU2001261752A AU6175201A AU2001261752A1 AU 2001261752 A1 AU2001261752 A1 AU 2001261752A1 AU 2001261752 A AU2001261752 A AU 2001261752A AU 6175201 A AU6175201 A AU 6175201A AU 2001261752 A1 AU2001261752 A1 AU 2001261752A1
- Authority
- AU
- Australia
- Prior art keywords
- ophthalmic
- compositions
- methods
- nasal infections
- treating otic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/575,850 US6509327B1 (en) | 1998-09-30 | 2000-05-19 | Compositions and methods for treating otic, ophthalmic and nasal infections |
| US09575850 | 2000-05-19 | ||
| PCT/US2001/016112 WO2001089496A2 (en) | 2000-05-19 | 2001-05-17 | Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001261752A1 true AU2001261752A1 (en) | 2001-12-03 |
Family
ID=24301946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001261752A Abandoned AU2001261752A1 (en) | 2000-05-19 | 2001-05-17 | Compositions and methods for treating otic, ophthalmic and nasal infections |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US6509327B1 (en) |
| AU (1) | AU2001261752A1 (en) |
| WO (1) | WO2001089496A2 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| DE60017180T2 (en) | 1999-10-08 | 2005-12-08 | Affinium Pharmaceuticals, Inc., Toronto | FAB I INHIBITORS |
| JP4387804B2 (en) * | 2001-04-06 | 2009-12-24 | アフィニアム・ファーマシューティカルズ・インコーポレイテッド | FabI inhibitor |
| SI1575951T1 (en) * | 2002-12-06 | 2014-10-30 | Debiopharm International Sa Forum "Apres-Demain" | Heterocyclic compounds, methods of making them and their use in therapy |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| DE602004016831D1 (en) | 2003-03-17 | 2008-11-13 | Affinium Pharm Inc | PHARMACEUTICAL COMPOSITIONS INHIBITORS OF FAB I AND OTHER ANTIBIOTICS CONTAINED |
| US20050004098A1 (en) * | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
| DK1608407T3 (en) * | 2003-03-20 | 2006-12-04 | Pharmacia Corp | Dispersible formulation of an anti-inflammatory agent |
| US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| US20050009931A1 (en) * | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| US20040202687A1 (en) * | 2003-04-14 | 2004-10-14 | Babu M.K. Manoj | Ciprofloxacin formulations and methods of making and using the same |
| US20050085446A1 (en) * | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| PL1666477T3 (en) | 2003-09-10 | 2013-11-29 | Kyorin Seiyaku Kk | 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) q uinolonecarboxylic acid derivative |
| US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EP2848614A3 (en) * | 2004-06-04 | 2015-07-29 | Debiopharm International SA | Acrylamide derivatives as antibiotic agents |
| AT501376B1 (en) * | 2005-01-17 | 2010-11-15 | Pregenzer Bruno | GLUCCOOCORTICOID MEDICINAL PRODUCT |
| US7981104B2 (en) * | 2005-01-25 | 2011-07-19 | Patrick Slater | Method for treating otitis externa |
| US8337481B2 (en) | 2005-01-25 | 2012-12-25 | Patrick Slater | Method for treating otitis externa |
| US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| WO2008098374A1 (en) | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
| WO2008143343A1 (en) * | 2007-05-24 | 2008-11-27 | Kyorin Pharmaceutical Co., Ltd. | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| ES2493641T3 (en) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Nasal administration of aqueous corticosteroid solutions |
| AU2009214461A1 (en) * | 2008-02-15 | 2009-08-20 | Alcon Research, Ltd. | Fluoroquinolone derivatives for ophthalmic applications |
| CN102026623B (en) | 2008-05-14 | 2013-08-14 | 奥德纳米有限公司 | Controlled-release corticosteroid compositions and methods for treating otic disorders |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
| CA2765852C (en) | 2009-07-02 | 2014-08-26 | Alcon Research, Ltd. | Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections |
| PL2802209T3 (en) * | 2012-01-10 | 2021-07-05 | Entrx LLC | Otic formulations |
| LT2861608T (en) | 2012-06-19 | 2019-07-10 | Debiopharm International Sa | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
| US9504691B2 (en) * | 2012-12-06 | 2016-11-29 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
| US9849126B2 (en) | 2013-01-03 | 2017-12-26 | Entrx LLC | Sterile otic formulations |
| JP2016534121A (en) | 2013-08-27 | 2016-11-04 | オトノミ—,インク. | Treatment of childhood ear disease |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| AU2017223037B2 (en) | 2016-02-26 | 2022-04-14 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
| US11040004B2 (en) | 2016-09-16 | 2021-06-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
| CN116327781A (en) | 2019-02-14 | 2023-06-27 | 德彪药业国际股份公司 | Alfarubicin preparation and preparation method thereof |
| MX2021015513A (en) | 2019-06-14 | 2022-04-20 | Debiopharm Int Sa | MEDICINE AND USE THEREOF TO TREAT BACTERIAL INFECTIONS INVOLVING A BIFILM. |
| EP3861985B1 (en) | 2020-02-06 | 2023-06-14 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
| CN115461040B (en) | 2020-03-25 | 2025-04-01 | 视尔普斯眼科公司 | Ocular implants containing tyrosine kinase inhibitors |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| EP4216929A1 (en) | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| AU2021347318A1 (en) | 2020-09-24 | 2023-03-23 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| US4670444B1 (en) | 1980-09-03 | 1999-02-09 | Bayer Ag | and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds |
| US4730013A (en) | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4551456A (en) | 1983-11-14 | 1985-11-05 | Merck & Co., Inc. | Ophthalmic use of norfloxacin and related antibiotics |
| US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| JPH089597B2 (en) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same |
| DE3704907A1 (en) | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
| US5591744A (en) | 1987-04-16 | 1997-01-07 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| US4920120A (en) | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
| US5149694A (en) | 1988-03-09 | 1992-09-22 | Alcon Laboratories, Inc. | Combination of tobramycin and dexamethasone for topical ophthalmic use |
| DE3906365A1 (en) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM |
| WO1990001933A1 (en) | 1988-08-26 | 1990-03-08 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
| US5360611A (en) | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US5185337A (en) | 1989-03-29 | 1993-02-09 | Otsuka Pharmaceutical Co., Ltd. | Pyrroloquinoline derivatives and pharmaceutical compositions for antimicrobial use |
| US5164402A (en) | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
| TW209865B (en) | 1992-01-10 | 1993-07-21 | Bayer Ag | |
| ES2079994B1 (en) * | 1992-10-07 | 1996-08-01 | Cusi Lab | PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE. |
| DE4234078A1 (en) | 1992-10-09 | 1994-04-14 | Bayer Ag | Quinolonecarboxylic acids |
| US5631004A (en) | 1993-09-30 | 1997-05-20 | Alcon Laboratories, Inc. | Use of sustained release antibiotic compositions in ophthalmic surgical procedures |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| ES2079320B1 (en) | 1994-05-17 | 1996-10-16 | Cusi Lab | OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS. |
| DE4424369A1 (en) | 1994-07-11 | 1996-01-18 | Bayer Ag | Pyrido [3,2,1.i, j] [3,1] benzoxazine derivatives |
| IL120317A (en) | 1995-06-06 | 2000-08-13 | Bayer Ag | Ciprofloxacin-hydrocortisone suspension |
| DE19546249A1 (en) | 1995-12-12 | 1997-06-19 | Bayer Ag | New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it |
| AU4151697A (en) | 1996-08-14 | 1998-03-06 | Vanderbilt University | Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia) |
| IL134591A0 (en) | 1997-09-25 | 2001-04-30 | Bayer Ag | Medicament formulation with a controlled release of an active agent |
| US5912255A (en) | 1998-02-27 | 1999-06-15 | Bussell; Letantia | Topical fluoroquinolone antibiotics combined with benzoyl peroxide |
| WO2000010570A1 (en) * | 1998-08-21 | 2000-03-02 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparations |
| GB9818258D0 (en) | 1998-08-21 | 1998-10-14 | Pfizer Ltd | Antifungal compositions |
| US6395746B1 (en) | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| AR020660A1 (en) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE |
| AR020661A1 (en) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| EP1117406A1 (en) | 1998-09-30 | 2001-07-25 | Alcon Laboratories, Inc. | Antibiotic compositions for treatment of the eye, ear and nose |
| US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| DE19962470A1 (en) | 1999-12-22 | 2001-07-12 | Schulz Hans Herrmann | Use of chemotherapy drugs |
| WO2001089495A2 (en) | 2000-05-19 | 2001-11-29 | Alcon Laboratories, Inc. | Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
-
2000
- 2000-05-19 US US09/575,850 patent/US6509327B1/en not_active Expired - Lifetime
-
2001
- 2001-05-17 WO PCT/US2001/016112 patent/WO2001089496A2/en not_active Ceased
- 2001-05-17 AU AU2001261752A patent/AU2001261752A1/en not_active Abandoned
-
2002
- 2002-09-24 US US10/253,335 patent/US20030069253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6509327B1 (en) | 2003-01-21 |
| WO2001089496A2 (en) | 2001-11-29 |
| US20030069253A1 (en) | 2003-04-10 |
| WO2001089496A3 (en) | 2002-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001261752A1 (en) | Compositions and methods for treating otic, ophthalmic and nasal infections | |
| AU2001228759A1 (en) | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols | |
| AU2001245437A1 (en) | Lightweight methods and compositions for well treating | |
| AU2001268564A1 (en) | Alpha-glycosylceramides for treating bacterial and fungal infections | |
| AU2001285143A1 (en) | Methods and compositions for targeted delivery | |
| AU2001289684A1 (en) | Glass-ceramics, process for their preparation and use | |
| AU2001269799A1 (en) | Methods for treating various eye disorders | |
| AU2001239774A1 (en) | Antibacterial agents and compositions, methods and systems employing same | |
| AU2002232558A1 (en) | Compounds, compositions and methods for treatment of parasitic infections | |
| AU2001253297A1 (en) | Sterilization process for air, liquid and surfaces | |
| AU2001237939A1 (en) | Methods for treating glaucoma | |
| AU2001277824A1 (en) | Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation | |
| AU2001275085A1 (en) | Methods, compounds and compositions for treating gout | |
| AU2003296963A1 (en) | Methods and compositions for treating and preventing ear infections | |
| AU2002324753A1 (en) | Composition and method for treating viral infection | |
| AU2002353774A1 (en) | Products and methods for treating microbial infections | |
| AU2001261748A1 (en) | Antibiotic compositions for treatment of the eye, ear and nose | |
| AU2001234616A1 (en) | Vaccine composition, process and methods | |
| AU2003237088A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
| AU2001258675A1 (en) | Treating infections | |
| AU2002350181A1 (en) | Compositions and methods for viral delivery | |
| AU2002342188A1 (en) | Methods and compositions for treating flavivirus-mediated disease | |
| AU2002353915A1 (en) | Methods and compositions for treating rotavirus-mediated disease | |
| AU2002361711A1 (en) | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832 | |
| AU2002355265A1 (en) | Methods and compositions for treating fungal infections |